Economic analyses of human genetics services: A systematic review

Genetics in Medicine

Volumn 7, Issue 8, 2005, Pages 519-523

  Carlson, Josh J ^b   Henrikson, Nora Beidler ^b   Veenstra, David L ^b   Ramsey, Scott D ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cost effectiveness; Economic evaluation; Genetic services; Genetic technologies; Genetic test

Indexed keywords

ANEUPLOIDY; CANCER; CLUSTER ANALYSIS; CONCEPTION; COST EFFECTIVENESS ANALYSIS; DATA BASE; ECONOMIC ASPECT; ECONOMIC EVALUATION; GENETIC PROCEDURES; GENETIC SERVICE; HUMAN; MEDICAL LITERATURE; OUTCOMES RESEARCH; PEDIATRICS; PRENATAL PERIOD; QUALITY ADJUSTED LIFE YEAR; RATING SCALE; REVIEW;

ADULT; COSTS AND COST ANALYSIS; GENETIC SERVICES; HUMANS; PUBLISHING;

EID: 27644465790     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GIM.0000182467.79495.e2     Document Type: Review

References (23)

1. Phillips KA, Van Bebber SL. A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics 2004;5(8):1139-1149.
2. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313(7052):275-283.
3. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. Oxford: Oxford University Press; 1997.
4. Gold MR, Siegal JE, Russel LB, Weinstein MC, eds. Cost-Effectiveness in Health and Mediane. New York: Oxford University Press; 1996.
5. Holtzman NA, Watson MS. Promoting safe and effective genetic testing in the United States. Final report of the Task Force on Genetic Testing. J Child Fam Nurs 1999;2(5):388-390.
6. Chiou CF, Hay JW, Wallace JF, Bloom BS, et al Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care 2003;41(1):32-44.
7. Spiegel BM, Targownik LE, Kanwal F, Derosa V, et al The quality of published health economic analyses in digestive diseases: a systematic review and quantitative appraisal. Gastroenterology 2004;127(2):403-411.
8. Ofman JJ, Sullivan SD, Neumann PJ, Chiou CF, et al Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm 2003;9(1):53-61.
9. The Global Initiative For Asthma Dissemination and Implementation of Asthma Guidelines. Available at: http://www.ginasthma.com/dis.pdf. Accessed January 10, 2005.
10. Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2004;22(5):854-863.
11. Higashi MK, Veenstra DL, del Aguila M, Hujoel P. The cost-effectiveness of interleukin-1 genetic testing for periodontal disease. J Periodontol 2002;73(12):1474-1484.
12. Eckman MH, Singh SK, Erban JK, Kao G. Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: a cost-effectiveness analysis. Med Decis Making 2002;22(2):108-124.
13. Marchetti M, Quaglini S, Barosi G. Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A. QJM 2001;94(7):365-372.
14. Marchetti M, Pistorio A, Barosi G. Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden-cost-effectiveness analysis. Thromb Haemost 2000;84(5):752-757.
15. Calvert NW, Morgan AB, Catto JW, Hamdy FC, et al Effectiveness and cost-effectiveness of prognostic markers in prostate cancer. Br J Cancer 2003;88(1):31-35.
16. Harris RA, Washington AE, Nease RF, Jr., Kuppermann M. Cost utility of prenatal diagnosis and the risk-based threshold. Lancet 2004;363(9405):276-282.
17. Auerbach AD, Sanders GD, Hambleton J. Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis. Am J Med 2004;116(12):816-828.
18. Rowley PT, Loader S, Kaplan RM. Prenatal screening for cystic fibrosis carriers: an economic evaluation. Am J Hum Genet 1998;63(4):1160-1174.
19. King CH, Fischler DF, Gerkin RD. Will genetic testing alter the management of disease caused by infectious agents? A cost-effectiveness analysis of gene-testing strategies for prevention of rheumatic fever. Clin Infect Dis 2002;34(11):1491-1499.
20. Schoen EJ, Baker JC, Colby CJ, To TT. Cost-benefit analysis of universal tandem mass spectrometry for newborn screening. Pediatrics 2002;110(4):781-786.
21. Venditti LN, Venditti CP, Berry GT, Kaplan PB, et al Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis. Pediatrics 2003;112(5):1005-1015.
22. Asberg A, Tretli S, Hveem K, Bjerve KS. Benefit of population-based screening for phenotypic hemochromatosis in young men. Scand J Gastroenterol 2002;37(10):1212-1219.
23. Adams PC, Valberg LS. Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping. Am J Gastroenterol 1999;94(6):1593-1600.